[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610196":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":49,"id":53,"slug":22,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":22,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":22,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":31,"whyStopped":22,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Kisspeptin pump","EXPERIMENTAL","SC administration of kisspeptin for two weeks (pulsatile)",[13],"Drug: kisspeptin 112-121",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","kisspeptin 112-121","SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)",[9],[21],"Metastin 45-54",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Study Coordinator","CONTACT","617-643-2308","MGHKisspeptinResearch@partners.org",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-71.05977,42.35843,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Stephanie B. Seminara, MD","Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine",[50],{"name":51,"class":52},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH","100610196",false,"NCT07224438","Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea","Inclusion Criteria:\n\n* Female\n* Ages 18-45 years\n* Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)\n* Normal blood pressure (systolic BP \\\u003C 140 mm Hg, diastolic \\\u003C 90 mm Hg)\n* Hemoglobin no less than 0.5 g\u002FdL below the lower limit of the reference range for normal women\n* Negative serum hCG pregnancy test\n* No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis OR willing to complete an appropriate washout for that particular medication and its method of administration\n* If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug\n\nExclusion Criteria:\n\n* Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in\u002Fcompletion of the protocol\n* Excessive alcohol consumption (\\>10 drinks\u002Fweek)\n* Active use of illicit drugs\n* Pregnant\n* Trying to become pregnant during protocol participation\n* Breast feeding\n* History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding","FEMALE","18 Years","45 Years",{"count":62,"type":63},20,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.",[69,70],"Hypothalamic Amenorrhea","Hypogonadotropic Hypogonadism",[72,73,74],"hypothalamic amenorrhea","hypogonadotropic hypogonadism","kisspeptin","2025-12-29",{"date":77,"type":78},"2025-12-31","ACTUAL",{"date":80,"type":78},"2025-12-09",{"date":82,"type":63},"2030-05",{"name":47,"class":6},1]